Abstract
Nail dystrophy is a heterogeneous skin condition and in some subtypes, is associated with autoimmune diseases in particular psoriasis and psoriatic arthritis. In this report, we show that tofacitinib, a novel therapy for rheumatoid arthritis, appears to be beneficial in patients with nail disease refractory to other conventional modes of therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lam S (2016) JAK inhibitors:a broadening approach in rheumatoid arthritis. Drugs Today 52:467–469
Fleischmann R1, Mease PJ2, Schwartzman S3, Hwang LJ4, Soma K5, Connell CA5, Takiya L6, Bananis E7 (2017) Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol 36(1):15–24
Roskoski R (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784–803
Kostovic K, Gulin SJ, Mokos ZB, Ceovic R (2017) Tofacitinib an oral Janus kinase inhibitor: perspectives in dermatology Curr Med Chem Jan 2012
Kasumagic-Halilovic E, Prohic A (2009) Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 23:240–241
Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134:2988–2990
Scheinberg M, Ferreira SB (2016) Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med 165:750–751
Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB (2016) Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol 8(3):262–266
Tosti A, Fanti PA, Morelli R, Bardazzi F (1991) Trachyonychia associated with alopecia areata: a clinical and pathological study. J Am Acad Dermatol 25:266–270
Dhayalan A, King BA (2016) Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol 152:492–493
Gao Q, Liang X, Shaikh AS, Zang J, Xu W, Zhang Y (2016) JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases. Curr Drug Targets 7
Liu LY, Craiglow BG, Dai F, King BA (2016) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol pii: S0190–9622(16)30763–0
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Jaller, J.A., Jaller, J.J., Jaller, A.M. et al. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol 36, 971–973 (2017). https://doi.org/10.1007/s10067-017-3574-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3574-0